FDA Approval in Bladder Cancer, Breakthrough Therapy Designation in DLBCL, and More

George R. Simon, MD, reports on an FDA approval in bladder cancer, a breakthrough therapy designation in diffuse large B-cell lymphoma, an ODAC hearing scheduled for a drug in HER2-positive breast cancer, an FDA elimination for REMS certification prior to select treatments, and 2 disappointing phase III results in non—small cell lung cancer and triple-negative breast cancer.